Complement inhibition as a proposed neuroprotective strategy following cardiac arrest

Brad E Zacharia1, Zachary L Hickman, Bartosz T Grobelny

  • 1Department of Neurological Surgery, Columbia University, New York, NY 10032, USA. bez2103@columbia.edu

Mediators of Inflammation
|February 13, 2010
PubMed

Insights

Out-of-hospital cardiac arrest (OHCA) causes significant brain injury. Complement inhibition shows promise for treating this global cerebral ischemia-reperfusion injury and improving patient outcomes after resuscitation.

Area of Science:

  • Neuroscience
  • Immunology
  • Emergency Medicine

Background:

  • Out-of-hospital cardiac arrest (OHCA) leads to significant neurological injury after resuscitation.
  • Effective treatments for global cerebral ischemia-reperfusion (GCI/R) injury post-OHCA are lacking.
  • The complement cascade is implicated in GCI/R injury pathogenesis.

Purpose of the Study:

  • To explore the pathophysiology of complement-mediated GCI/R injury following OHCA.
  • To highlight complement inhibition as a potential neuroprotective strategy.

Main Methods:

  • Review of preclinical and clinical evidence.
  • Analysis of the role of complement activation in GCI/R injury.

Main Results:

  • Complement cascade activation is critical in GCI/R injury following OHCA.
  • Complement inhibition has demonstrated efficacy in experimental brain ischemia models.

Conclusions:

  • Complement inhibition represents a promising therapeutic target for mitigating GCI/R injury.
  • Augmenting current treatments with complement inhibition could improve outcomes for OHCA survivors.

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...